| Name: | (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid |
| CAS Number: | 128-13-2 |  3D/inchi
|
| Other(deleted CASRN): | 50809-41-1 |
| ECHA EINECS - REACH Pre-Reg: | 204-879-3 |
| FDA UNII: | 724L30Y2QR |
| Nikkaji Web: | J2.520H |
| Beilstein Number: | 3219888 |
| MDL: | MFCD00003680 |
| XlogP3-AA: | 4.90 (est) |
| Molecular Weight: | 392.57960000 |
| Formula: | C24 H40 O4 |
| BioActivity Summary: | listing |
| NMR Predictor: | Predict (works with chrome, Edge or firefox) |
Category:cosmetic agents
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 203.00 °C. @ 760.00 mm Hg
|
| Boiling Point: | 547.10 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 570.00 °F. TCC ( 298.80 °C. ) (est)
|
| logP (o/w): | 3.000 |
| Soluble in: |
| | water, 20 mg/L @ 20 °C (exp) | | | water, 2.414 mg/L @ 25 °C (est) |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intraperitoneal-mouse LD50 1200 mg/kg
SKIN AND APPENDAGES (SKIN): HAIR: OTHER
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Kiso to Rinsho. Clinical Report. Vol. 9, Pg. 3159, 1975.
intravenous-mouse LD50 240 mg/kg
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Kiso to Rinsho. Clinical Report. Vol. 9, Pg. 3159, 1975.
oral-mouse LD50 > 10000 mg/kg
Kiso to Rinsho. Clinical Report. Vol. 9, Pg. 3159, 1975.
intraperitoneal-rat LD50 700 mg/kg
Bollettino Chimico Farmaceutico. Vol. 126, Pg. 282, 1987.
intravenous-rat LD50 310 mg/kg
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Kiso to Rinsho. Clinical Report. Vol. 9, Pg. 3159, 1975.
oral-rat LD50 4600 mg/kg
Bollettino Chimico Farmaceutico. Vol. 126, Pg. 282, 1987.
|
| Dermal Toxicity: |
subcutaneous-mouse LD50 1000 mg/kg
"Modern Pharmaceuticals of Japan, IV," Tokyo, Japan Pharmaceutical, Medical and Dental Supply Exporters' Assoc., 1972Vol. -, Pg. 109, 1972.
subcutaneous-rat LD50 > 2000 mg/kg
Kiso to Rinsho. Clinical Report. Vol. 9, Pg. 3159, 1975.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | | cosmetic agents |
| Recommendation for ursodiol usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for ursodiol flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
| EPI System: View |
| ClinicalTrials.gov:search |
| Daily Med:search |
| Chemical Carcinogenesis Research Information System:Search |
| AIDS Citations:Search |
| Cancer Citations:Search |
| Toxicology Citations:Search |
| EPA ACToR:Toxicology Data |
| EPA Substance Registry Services (SRS):Registry |
| Laboratory Chemical Safety Summary :31401 |
| National Institute of Allergy and Infectious Diseases:Data |
| WGK Germany:2 |
| (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid |
| Chemidplus:0000128132 |
| RTECS:FZ2000000 for cas# 128-13-2 |
References:
| | (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid |
| NIST Chemistry WebBook: | Search Inchi |
| Pubchem (cid): | 31401 |
| Pubchem (sid): | 134974576 |
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| | actigall | | | arsacol | | | cholit-ursan | | | delursan | | | destolit | | | deursil | | (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7- | dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid | | 3-alpha,7-beta- | dihydroxy-5-beta-cholanoic acid | | 3,7- | dihydroxycholan-24-oic acid | | 3-alpha,7-beta- | dihydroxycholanic acid | | 3-alpha,7-beta- | dioxycholanic acid | | 7-beta- | hydroxylithocholic acid | | | litursol | | | lyeton | | 17-beta-(1- | methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol | | | peptarom | | | solutrat | | | urso 250 | | | urso DS | | | urso forte | | | ursobilin | | | ursochol | | | ursocholic acid, deoxy- | | | ursodeoxycholic acid | | | ursodesoxycholic acid | | | ursofalk | | | ursolvan
|
Articles:
| PubMed:Variation of pathways and network profiles reveals the differential pharmacological mechanisms of each effective component to treat middle cerebral artery ischemia-reperfusion mice. |
| PubMed:Hepatopathy following consumption of a commercially available blue-green algae dietary supplement in a dog. |
| PubMed:Bile Acids Reduce Prion Conversion, Reduce Neuronal Loss, and Prolong Male Survival in Models of Prion Disease. |
| PubMed:Anticancer Effect of Ursodeoxycholic Acid in Human Oral Squamous Carcinoma HSC-3 Cells through the Caspases. |
| PubMed:Cholesterol lowering effect in the gall bladder of dogs by a standardized infusion of Herniaria hirsuta L. |
| PubMed:New therapies for primary biliary cirrhosis. |
| PubMed:The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases. |
| PubMed:Modulation of GSH with exogenous agents leads to changes in glyoxalase 1 enzyme activity in VL-17A cells exposed to chronic alcohol plus high glucose. |
| PubMed:Determination of bile acids by hollow fibre liquid-phase microextraction coupled with gas chromatography. |
| PubMed:Refeeding syndrome in a patient with advanced kidney failure due to nephronophthisis. |
| PubMed:[Rapid identification of two new isomers in bear bile powder by LC-Q-TOF-MS combined with PCC oxidation]. |
| PubMed:Extraction of lycopene from tomato paste by ursodeoxycholic acid using the selective inclusion complex method. |
| PubMed:Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. |
| PubMed:Primary biliary cirrhosis: therapeutic advances. |
| PubMed:[Modern approaches to the treatment of biliary pathology in young patients with obesity]. |
| PubMed:Anti-oxidant and natural killer cell activity of Korean red ginseng (Panax ginseng) and urushiol (Rhus vernicifera Stokes) on non-alcoholic fatty liver disease of rat. |
| PubMed:Ursodeoxycholic acid for primary biliary cirrhosis. |
| PubMed:Effects of Korean red ginseng as an adjuvant to bile acids in medical dissolution therapy for gallstones: a prospective, randomized, controlled, double-blind pilot trial. |
| PubMed:B cell depletion in treating primary biliary cirrhosis: pros and cons. |
| PubMed:Dietary polyamine intake and risk of colorectal adenomatous polyps. |
| PubMed:Ursodeoxycholic acid treatment in a rat model of cancer cachexia. |
| PubMed:Protective effect of Öküzgözü (Vitis vinifera L. cv.) grape juice against carbon tetrachloride induced oxidative stress in rats. |
| PubMed:Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. |
| PubMed:Linking endoplasmic reticulum stress to cell death in hepatocytes: roles of C/EBP homologous protein and chemical chaperones in palmitate-mediated cell death. |
| PubMed:Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies. |
| PubMed:[Non-alcoholic fatty liver disease and cardiovascular risk]. |
| PubMed:Folate fortification, plasma folate, homocysteine and colorectal adenoma recurrence. |
| PubMed:Hepatoprotective bile acid 'ursodeoxycholic acid (UDCA)' Property and difference as bile acids. |
| PubMed:Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria. |
| PubMed:Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? |
| PubMed:[Pharmacological capacities of the prevention of colorectal cancer]. |
| PubMed:Hepatic branch vagotomy can block liver regeneration enhanced by ursodesoxycholic acid in 66% hepatectomized rats. |
| PubMed:Postprandial changes in serum unconjugated bile acid concentrations in healthy beagles. |
| PubMed:[Influence of ursodeoxycholic acid on the therapeutic effects of low-calorie diet in obesity and hyperlipidemia rats with steatohepatitis]. |
| PubMed:Dietary iron restriction improves aminotransferase levels in chronic hepatitis C patients. |
| PubMed:Stability of oral suspensions of ursodiol made from tablets. |
| PubMed:Chemoprevention of colorectal cancer. |
| PubMed:[3 beta-Hydroxysteroid-delta 5-oxidoreductase/isomerase deficiency]. |
| PubMed:Apolipoprotein E polymorphism in alagille syndrome and progressive familial intrahepatic cholestasis. |
| PubMed:Modulation of colonic xenobiotic metabolizing enzymes by feeding bile acids: comparative effects of cholic, deoxycholic, lithocholic and ursodeoxycholic acids. |
| PubMed:Studies on N-nitroso bile acid amides in relation to their possible role in gastrointestinal cancer. |
| PubMed:The indirect UV detection in the analysis of ursodeoxycholic acid and related compounds by HPCE. |
| PubMed:Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. |
| PubMed:Advances in parenteral nutrition. |
| PubMed:Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. |
| PubMed:Functional dyspepsia: how could a biliary dyspepsia sub-group be recognized? A methodological approach. |
| PubMed:Extreme hyperbilirubinemia associated with the use of anabolic steroids, health/nutritional supplements, and ethanol: response to ursodeoxycholic acid treatment. |
| PubMed:Chemo- and dietary prevention of colorectal cancer. |
| PubMed:Effects of different formula feeds on the developmental pattern of urinary bile acid excretion in infants. |
| PubMed:Gallstone lithotripsy. |
| PubMed:Effects of massive small bowel resection on metabolism of bile acids and vitamin D3 and gastrin release in dogs. |
| PubMed:Increased gallbladder residual volume in nonresponders to extracorporeal shock wave lithotripsy of gallbladder stones. |
| PubMed:Lack of benefit of ursodeoxycholic acid in drug-induced cholestasis in the rat. |
| PubMed:Feeding diets containing 2% cheno- or urso-deoxycholic acid or cholestyramine to rats for two weeks alters intestinal morphology and bile acid absorption. |
| PubMed:Medical management of gallstones: a cost-effectiveness analysis. |
| PubMed:Effect of ursodeoxycholic acid (UDCA) on pancreatic enzyme secretion and gallbladder emptying. |
| PubMed:Effect of aging and dietary restriction on bile acid metabolism in rats. |
| PubMed:Extracorporeal shock-wave lithotripsy of gallstones: Boston experience with the Dornier MPL 9000 lithotripter. |
| PubMed:Ursodiol: a cholesterol gallstone solubilizing agent. |
| PubMed:In vitro transformation of cheno- and ursodeoxycholic acids and their 7-oleyl esters by human intestinal microflora. |
| PubMed:Transformation of sulfated bile acids by human intestinal microflora. |
| PubMed:Feeding rats diets containing cheno- or ursodeoxycholic acid or cholestyramine modifies intestinal uptake of glucose and lipids. |
| PubMed:Serum bile acids in Gilbert's syndrome after oral load of chenodeoxycholic acid. |
| PubMed:Epimerization of the four 3,7-dihydroxy bile acid epimers by human fecal microorganisms in anaerobic mixed cultures and in feces. |
| PubMed:A treatment of non-ketotic hyperglycinaemia. |
| PubMed:Dissolution of cholesterol gallstones by bile acids in hamsters. |
| PubMed:Effect of cecum and appendix on 7 alpha-dehydroxylation and 7 beta-epimerization of chenodeoxycholic acid in the rabbit. |
| PubMed:Cholesterol gallstone formation and prevention by chenodeoxycholic and ursodeoxycholic acids. A new hamster model. |
|
